Role of Cinacalcet in Treating Cardiac Dysfunction Secondary to Hyperparathyroidism: A Case Series

Area of Science:

• Pediatric Nephrology
• Cardiology
• Endocrinology

Background:

• Cardiovascular disease (CVD) is a primary cause of mortality in pediatric patients with chronic kidney disease (CKD).
• Disordered calcium-phosphate metabolism is strongly linked to cardiac dysfunction in CKD.
• Limited research exists on cinacalcet's efficacy and safety in children with CKD, particularly regarding cardiac complications.

Observation:

• Three pediatric patients with CKD on continuous ambulatory peritoneal dialysis (CAPD) presented with cardiac dysfunction and refractory hyperparathyroidism.
• Patients were treated with a low, weight-adjusted dose of cinacalcet (0.2 mg/kg/day), with monthly dose titration to target intact parathyroid hormone (iPTH) levels.
• Serum calcium, phosphorus, iPTH, and cardiac function via echocardiography were monitored monthly.

Findings:

• Cinacalcet therapy was initiated in three children with CKD, CAPD, cardiac dysfunction, and refractory hyperparathyroidism.
• Treatment involved a low adult weight-adjusted dose, titrated monthly to achieve target iPTH levels (200-300 pg/ml).
• No significant adverse effects related to cinacalcet were observed during the study period.

Implications:

• Cinacalcet may be a safe and potentially effective treatment option for managing cardiac dysfunction in pediatric CKD patients with hyperparathyroidism.
• Further research is warranted to confirm these findings in larger pediatric cohorts.
• This approach could help mitigate cardiovascular risks associated with CKD in children.